Beximco Pharmaceuticals Toekomstige groei
Future criteriumcontroles 2/6
Beximco Pharmaceuticals is forecast to grow earnings and revenue by 15.6% and 12.8% per annum respectively. EPS is expected to grow by 18.3% per annum. Return on equity is forecast to be 14.8% in 3 years.
Belangrijke informatie
15.6%
Groei van de winst
18.3%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 17.1% |
Inkomstengroei | 12.8% |
Toekomstig rendement op eigen vermogen | 14.8% |
Dekking van analisten | Low |
Laatst bijgewerkt | 09 May 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
6/30/2027 | 64,949 | 8,688 | 7,352 | 9,216 | 3 |
6/30/2026 | 57,171 | 7,464 | 6,868 | 8,545 | 3 |
6/30/2025 | 50,423 | 6,244 | 5,719 | 7,151 | 3 |
6/30/2024 | 44,506 | 5,251 | 4,894 | 6,146 | 3 |
3/31/2024 | 43,085 | 5,330 | 5,962 | 8,373 | N/A |
12/31/2023 | 41,652 | 4,916 | 5,696 | 8,176 | N/A |
9/30/2023 | 40,639 | 4,720 | 5,486 | 8,109 | N/A |
6/30/2023 | 39,267 | 4,614 | 3,442 | 6,085 | N/A |
3/31/2023 | 37,974 | 4,477 | 2,650 | 5,562 | N/A |
12/31/2022 | 37,379 | 4,629 | 1,323 | 3,922 | N/A |
9/30/2022 | 35,987 | 5,105 | 1,161 | 3,910 | N/A |
6/30/2022 | 34,669 | 5,123 | 2,275 | 5,214 | N/A |
3/31/2022 | 33,660 | 5,738 | 3,143 | 5,950 | N/A |
12/31/2021 | 32,062 | 6,097 | 4,153 | 7,502 | N/A |
9/30/2021 | 31,037 | 5,519 | 3,983 | 6,796 | N/A |
6/30/2021 | 29,494 | 5,128 | 3,465 | 6,023 | N/A |
3/31/2021 | 28,269 | 4,578 | 3,667 | 5,592 | N/A |
12/31/2020 | 27,517 | 4,017 | 2,198 | 4,025 | N/A |
9/30/2020 | 26,235 | 3,724 | 2,354 | 4,895 | N/A |
6/30/2020 | 25,612 | 3,515 | 3,267 | 5,542 | N/A |
3/31/2020 | 25,056 | 3,405 | -187 | 4,319 | N/A |
12/31/2019 | 24,202 | 3,251 | 834 | 5,814 | N/A |
9/30/2019 | 23,735 | 3,143 | -114 | 4,397 | N/A |
6/30/2019 | 22,817 | 3,033 | -1,585 | 2,960 | N/A |
3/31/2019 | 21,724 | 2,852 | -300 | 2,893 | N/A |
12/31/2018 | 20,188 | 2,708 | -2,393 | 1,397 | N/A |
9/30/2018 | 18,823 | 2,647 | -3,106 | 1,611 | N/A |
6/30/2018 | 17,717 | 2,537 | -3,239 | 1,819 | N/A |
3/31/2018 | 16,924 | 2,513 | -2,547 | 2,416 | N/A |
12/31/2017 | 16,517 | 2,431 | N/A | 2,873 | N/A |
9/30/2017 | 16,022 | 2,356 | N/A | 2,643 | N/A |
6/30/2017 | 15,509 | 2,227 | N/A | 2,634 | N/A |
3/31/2017 | 14,687 | 2,224 | N/A | 2,042 | N/A |
12/31/2016 | 14,271 | 2,133 | N/A | 1,883 | N/A |
9/30/2016 | 13,736 | 2,060 | N/A | 1,932 | N/A |
6/30/2016 | 13,356 | 1,965 | N/A | 2,113 | N/A |
12/31/2015 | 12,966 | 1,954 | N/A | 1,835 | N/A |
9/30/2015 | 12,573 | 1,804 | N/A | 2,095 | N/A |
6/30/2015 | 12,134 | 1,813 | N/A | 1,937 | N/A |
3/31/2015 | 11,628 | 1,605 | N/A | 2,510 | N/A |
12/31/2014 | 11,207 | 1,528 | N/A | 2,216 | N/A |
9/30/2014 | 11,139 | 1,476 | N/A | 2,459 | N/A |
6/30/2014 | 10,847 | 1,471 | N/A | 2,146 | N/A |
3/31/2014 | 10,804 | 1,452 | N/A | 2,196 | N/A |
12/31/2013 | 10,491 | 1,405 | N/A | 2,130 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: BXPHARMA's forecast earnings growth (15.6% per year) is above the savings rate (3.7%).
Winst versus markt: BXPHARMA's earnings (15.6% per year) are forecast to grow slower than the BD market (17.3% per year).
Hoge groeiwinsten: BXPHARMA's earnings are forecast to grow, but not significantly.
Omzet versus markt: BXPHARMA's revenue (12.8% per year) is forecast to grow faster than the BD market (9.3% per year).
Hoge groei-inkomsten: BXPHARMA's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: BXPHARMA's Return on Equity is forecast to be low in 3 years time (14.8%).